Wednesday, March 05, 2025 | 11:04 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Suven Life Sciences secures two product patents

Image

Capital Market

One each in South Korea and USA

Suven Life Sciences announced that its drug discovery portfolio which has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators resulted in the grant of one (1) product patent from USA (8735423) and one (1) product patent from South Korea (10-1410903) corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

 

With these new patents, Suven has a total of nineteen (19) granted patents from USA and fifteen (15) granted patents from South Korea.

Powered by Capital Market - Live News

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 13 2014 | 11:46 AM IST

Explore News